Genes & Development Submission Guide: Portal, 9-Day Triage & Single-Revision Rule

Source: Genes & Development Information for Authors, Clarivate JCR 2024, CSHL Press editorial materials, accessed May 2026.

Genes & Development publishes three primary article types with character-count rather than word-count conventions.

Main file is a single merged PDF (text plus figures). Supplementary materials upload separately.

Source: Genes & Development Information for Authors.

Genes & Development operates a two-stage timeline: in-house triage first (9-day median), peer review for manuscripts that clear triage (45-day median first decision).

Day 0: Submission via submit.genesdev.org

Submission lands in the Bench>Press portal. Automated technical checks run on PDF format, single-file main manuscript, and declaration completeness.

Day 1 to 9: Editorial triage (in-house, returned-without-review window)

The editors read the cover letter, abstract, and PDF for mechanistic advance and broad biological significance. Returned-without-review decisions arrive at the ~9-day median for unsuitable manuscripts. CSHL Press is explicit: papers deemed unsuitable are returned without review.

Week 2 to 6: Peer review (for manuscripts that clear triage)

Single-blind peer review runs across this window. Typically 2 to 3 reviewers per manuscript.

Day 45: First decision (median for reviewed manuscripts)

Decision arrives at the 45-day median from submission for manuscripts that pass triage. Major revision is the most common outcome; minor revision for stronger submissions.

Week 8 to 12: Single-revision window

Authors complete the one revision cycle the journal typically considers. The single-revision policy means revisions must address all major concerns; second revision rounds are uncommon.

Week 12 to 16: Final decision and production

Final decision and production typically complete within 12 to 16 weeks of submission for accepted manuscripts.

Source: Livewrite Genes & Development mirror, accessed May 2026.

The single most consequential decision before submission is which CSHL Press journal to target. The four-journal portfolio routes work based on the protagonist of the molecular contribution.

The CSHL Press routing rule: molecular-biology-as-protagonist work goes to Genes & Development; genomics-as-protagonist goes to Genome Research; RNA-as-protagonist goes to RNA; behavior-as-protagonist goes to Learning & Memory. Authors use the presubmission inquiry to resolve protagonist questions before formal submission.

Genes & Development editors triage on three operational signals beyond the format check:

1. Mechanistic advance, not technical demonstration. The cover letter and abstract must name a specific mechanistic claim that the data support directly, not indirectly. Indirect causal claims (correlation without causation, suggestive without definitive) return at triage.
2. Broad biological significance beyond the immediate system. The contribution must matter beyond the immediate experimental system. Importance visible only to insiders within a narrow specialist subcommunity routes to specialty venues at triage.
3. CSHL Press portfolio fit. Manuscripts that fit Genome Research, RNA, or Learning & Memory better get redirected within the CSHL Press family. The presubmission inquiry pathway exists precisely to resolve this before formal submission and the 9-day triage clock.

Recent issues span chromatin biology and epigenetics, RNA biology with mechanism, transcription factor and developmental regulation, signaling networks with molecular detail, cell cycle and DNA damage response, stem cell biology with molecular mechanism, organelle biology with mechanistic insight, and emerging molecular-biology methodologies including CRISPR-based functional genomics, single-cell mechanism, and structure-function integration.

For specific recent papers, see Genes & Development on CSHL Press.

In our pre-submission review work with molecular-biology manuscripts targeting Genes & Development, three patterns generate the most consistent returned-without-review outcomes in the 9-day triage window. Each pattern is visible across the abstract, cover letter, main figures, methods, supplementary material, data-deposition statement, and references before peer reviewers are invited.

This guide tells you what Genes & Development editors look for before reviewer assignment, and Manusights checks whether YOUR paper passes the mechanistic-advance, broad-significance, single-revision, data-deposition, main-figure, supplementary-evidence, and cover-letter tests that official CSHL Press guidance cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.

Mechanistic claim still indirect

In our pre-submission review work with molecular-biology manuscripts targeting Genes & Development, the most common triage failure is a manuscript that implies mechanism without proving the causal step. The abstract claims a regulator controls development, chromatin state, transcription, RNA processing, cell fate, or disease biology, but the figures show correlation, perturbation side effects, or indirect readouts. Genes & Development is explicit about novel mechanistic insight. A clean association is rarely enough.

The manuscript components should make direct mechanism visible. The cover letter should state the causal advance in one sentence. The abstract should name what is now known mechanistically, not only what phenotype changed. Main figures should include perturbation, rescue, biochemical reconstitution, structural evidence, genetic epistasis, time-course logic, or orthogonal validation where relevant. Methods should make the causal tests reproducible. Supplementary files should support, not replace, the central mechanism. Data deposition should cover sequencing, proteomics, structure, or imaging datasets where applicable. References should position the work against Genes & Development, Molecular Cell, Developmental Cell, Genome Research, RNA, and EMBO Journal comparators. If the strongest evidence is genomics-first, Genome Research may fit. If RNA biology is the protagonist, RNA may fit. If the story is narrower but mechanistically solid, a specialty molecular-biology venue can be more efficient.

Check whether your Genes & Development mechanism is directly proven →

Broad biological significance outruns the figures

In our pre-submission review work with molecular-biology manuscripts targeting Genes & Development, the second recurring returned-without-review pattern is significance framing that is stronger than the evidence. The cover letter may claim broad biological importance, but the figures show a narrow model-system observation, one cell line, one developmental stage, one pathway branch, or one disease context. CSHL Press editors are not only asking whether the data are clean. They are asking whether the manuscript matters beyond the immediate specialist audience.

The fix is claim discipline. The abstract should state the significance the figures actually support. The introduction should explain the broader biological question without inflating the result. Main figures should include the experiment that lets a reader outside the niche care: conservation, generality across systems, causal placement in a pathway, or a disease-relevant mechanism. The cover letter should not promise Cell-level breadth if the manuscript is better suited to Genes & Development's molecular-mechanism readership, and it should not promise Genes & Development breadth if the work is a specialty story. References should include broad biological comparators, not only a narrow literature lineage. If the significance is strongest in cell biology, Molecular Cell or Developmental Cell may be cleaner. If the paper is technically strong but narrower, EMBO Reports, Development, or a field-specific molecular biology journal can be a better route.

Check whether your Genes & Development significance claim matches the figures →

Single-revision policy ignored at initial submission

In our pre-submission review work with molecular-biology manuscripts targeting Genes & Development, a third recurring risk is submitting a manuscript that still needs a multi-round revision arc. The journal's single-revision policy means the first submission should already be near-final scientifically. Authors coming from venues where reviewers can ask for multiple rounds often underestimate this. A manuscript with one missing causal experiment, incomplete data deposition, unsettled figure logic, or a speculative model figure can fail not because the idea is weak, but because the revision burden is too large.

The submission package should be built as if there will be one chance to fix it. The cover letter should not ask reviewers to imagine the missing experiment. The abstract should not depend on supplementary-only evidence. Main figures should be publication-grade and mechanistically ordered. Methods and data deposition should be complete before upload. Supplementary files should be named and structured under CSHL rules. The references should include the closest competing mechanisms so the editor can see novelty immediately. The presubmission inquiry path exists for borderline portfolio fit across Genes & Development, Genome Research, RNA, and Learning & Memory. Use it when the protagonist is unclear. Genes & Development is strongest when the manuscript enters triage already single-revision-ready.

Check whether your Genes & Development initial package is single-revision-ready →

Check whether your Genes & Development manuscript passes the Sullivan-pass substance screen →

• Is Genes & Development a good journal?
• Genes & Development journal overview
• Genes & Development review time
• Genome Research Submission Guide
• Molecular Cell Submission Guide
• Developmental Cell Submission Guide

Last verified: May 2026 against Genes & Development editorial pages and CSHL Press author resources.

If you have already submitted, see Genes & Development Under Review for the portal meaning, follow-up threshold, and reviewer-risk preparation window. That status page connects this guide to the live waiting period after submission.